Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Last updated: January 14, 2019
Sponsor: Yuhan Corporation
Overall Status: Completed

Phase

3

Condition

Stress

Elevated Triglycerides (Hypertriglyceridemia)

Hypertriglyceridemia

Treatment

N/A

Clinical Study ID

NCT03067688
YHP1604-301
  • Ages > 19
  • All Genders

Study Summary

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Signed informed consent

  2. Subjects with hypertension and hyperlipidemia

Exclusion

Exclusion Criteria:

  1. Patients with known or suspected secondary hypertension

  2. Other exclusions applied

Study Design

Total Participants: 202
Study Start date:
April 11, 2017
Estimated Completion Date:
March 27, 2018

Study Description

This trial is a phase 3 study to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.

In "Temisartan/Amlodipine/Rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Amlodipine/Rosuvastatin" 8 for weeks.

In "Temisartan/Amlodipine" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Amlodipine" for 8 weeks.

In "Temisartan/Rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Rosuvastatin" for 8 weeks.

Connect with a study center

  • Seoul Natuional University Hospital

    Seoul, Jongno 03080
    Korea, Republic of

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.